NCI Grant Funds Study of Anti-Cancer Drugs to Treat Aggressive Breast Cancer

A University of Florida Health Cancer Center researcher has received a two-year $400,000 grant from the National Cancer Institute to evaluate a new class of anti-cancer drugs to treat aggressive types of breast cancer.

Brian Law, Ph.D., an associate professor in the department of pharmacology and therapeutics in the UF College of Medicine, aims to characterize the pharmacokinetic and pharmacodynamic properties of disulfide bond disrupting agents (DDAs). In animal models, these chemical agents have been shown to induce regression of primary tumors and metastatic lesions of drug-resistant patient-derived tumors. 

In the new project, Law aims to optimize the pharmacological properties of DDAs and dosing to guide future investigational new drug studies. The project will also validate biomarkers to predict tumor sensitivity to DDAs and monitor target engagement, as well as evaluate any adverse effects of DDAs on normal tissues or animal health.

Read more about NCI Grant Funds Study of Anti-Cancer Drugs To Treat Aggressive Breast Cancer.